Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394337 | 0.94 | LMNA (0.50) | PTGS2LMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL3943716 | 0.88 | PTGS2 (0.49) | PTGS2MEN1KMT2APTGS1FAAH | |
| SCHEMBL3939205 | 0.85 | SMN1; SMN2 (0.46) | LMNAHTTSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL5781556 | 0.85 | PTGS2 (0.52) | PTGS2HTTALDH1A1GAANPSR1 | |
| SCHEMBL396401 | 0.85 | SMN1; SMN2 (0.48) | LMNAHTTSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3948302 | 0.83 | PTGS2 (0.60) | PTGS2HTTALDH1A1GAANPSR1 | |
| SCHEMBL5781382 | 0.83 | PTGS2 (0.60) | PTGS2HTTALDH1A1GAANPSR1 | |
| SCHEMBL3942079 | 0.82 | MAPK11 (0.50) | PTGS2SMN1; SMN2ALDH1A1PTGS1 | |
| SCHEMBL5780346 | 0.81 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL3938737 | 0.79 | MEN1 (0.57) | PTGS2LMNAMAPTALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270399-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1043317-B1 | PYRIDAZINE DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS ACTIVE INGREDIENT | KOWA CO (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090069332-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-2017266-A1 | Pyridazine derivatives and medicines containing the same as effective ingredients | Kowa Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080119474-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20070208025-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070049595-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20060160804-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| US-20050267113-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2005-12-01 | — | — | US | disclosed |
| US-20050065155-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2005-03-24 | — | — | US | disclosed |
| US-20040147516-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20020123496-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2002-09-05 | — | — | US | disclosed |
| US-6348468-B1 | THESE COMPOUNDS HAVE EXCELLENT INHIBITORY ACTIVITY AGAINST INTERLEUKIN-1.BETA. PRODUCTION, IMMUNE SYSTEM DISEASES, INFLAMMATORY DISEASES, ISCHEMIC DISEASES AND THE LIKE. | KOWA CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1043317-A1 | NOVEL PYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Kowa Co., Ltd. (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208025-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | PTGS2 28/4885LMNA 1304/4885HTT 3829/4885 |
| US-20050267113-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IL1R1, IRAK1 | PTGS2 31/4885LMNA 893/4885HTT 3286/4885 |
| US-20090270399-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | PTGS2 31/4885LMNA 1438/4885HTT 3839/4885 |
| US-20050065155-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | PTGS2 28/4885LMNA 1434/4885HTT 4022/4885 |
| US-20040147516-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IRAK1, TLR1 | PTGS2 26/4885LMNA 1874/4885HTT 4076/4885 |
| US-20070049595-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | PTGS2 28/4885LMNA 1434/4885HTT 4022/4885 |
| US-20060160804-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | PTGS2 28/4885LMNA 1434/4885HTT 4022/4885 |
| US-20090069332-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | PTGS2 31/4885LMNA 1438/4885HTT 3839/4885 |
| US-20020123496-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IRAK1, TLR1 | PTGS2 26/4885LMNA 1874/4885HTT 4076/4885 |
| US-20080119474-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | PTGS2 28/4885LMNA 1304/4885HTT 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.